Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Israeli Initiatives Seek to Sidestep Funding Crisis
Dearth of Venture Capital Spawns Innovative Actions to Invigorate Country’s Life Science Industry
- Regardless of the ambient economic climate—which is, needless to say at the moment quite chilly—obtaining funding to support a start-up biotech company and to commercialize an early-stage product or technology is difficult. The situation is not very different in Israel, despite an abundance of world-class academic and research institutions ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.